Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients.
The pharmacokinetics of meropenem were characterized in 20 patients with different degrees of renal function who underwent continuous renal replacement therapy. Previously, no differences were detected in vitro in the removal of meropenem by continuous venovenous hemofiltration or continuous venovenous hemodialysis or when AN69 or polysulfone membranes were compared. In patients, no significant differences in the sieving coefficient or the saturation coefficient with the renal function were found, and the mean sieving coefficient/saturation coefficient value (0.80 +/- 0.12) was similar to the unbound fraction (0.79 +/- 0.08). An increase in total clearance and a decrease in elimination half-life were observed to the extent that the patient's creatinine clearance was higher. Likewise, the contribution of continuous renal replacement therapy to total clearance diminished in patients with less renal impairment. The results suggest that the renal function of the patient may influence meropenem pharmacokinetics during continuous renal replacement therapy. The lower trough plasma levels observed in nonrenal patients would not lead to adequate time during which serum drug concentrations are above the minimum inhibitory concentration values in many infections.
Isla
Arantxazu
A
Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria-Gasteiz, Spain.
Maynar
Javier
J
Sánchez-Izquierdo
José Angel
JA
Gascón
Alicia R
AR
Arzuaga
Alazne
A
Corral
Esther
E
Pedraz
José Luis
JL
D000180:Acrylic Resins; D000181:Acrylonitrile / Q000031:analogs & derivatives; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000476:Alkanesulfonates; D000900:Anti-Bacterial Agents / Q000737:chemistry* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D017583:Hemodiafiltration / Q000379:methods; D006440:Hemofiltration / Q000379:methods; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008567:Membranes, Artificial; D000077731:Meropenem; D008875:Middle Aged; D010539:Permeability; D011108:Polymers; D013450:Sulfones; D013845:Thienamycins / Q000737:chemistry* / Q000493:pharmacokinetics* / Q000627:therapeutic use
D000180:Acrylic Resins; D000476:Alkanesulfonates; D000900:Anti-Bacterial Agents; D008567:Membranes, Artificial; D011108:Polymers; D013450:Sulfones; D013845:Thienamycins; C017662:polysulfone P 1700; C016892:AN-69; C056081:methallyl sulfonate; D000077731:Meropenem; D000181:Acrylonitrile